U.S., May 9 -- ClinicalTrials.gov registry received information related to the study (NCT07576699) titled 'CK0802 for Treatment of Steroid Refractory Graft vs. Host Disease (GVHD)' on May 01.
Brief Summary: The purpose of this study is to determine the efficacy and safety of CK0802 Tregs for treatment of refractory GVHD (graft-versus-host disease)
Study Start Date: July 01
Study Type: INTERVENTIONAL
Condition:
Steroid Refractory Graft Versus Host Disease
Intervention:
BIOLOGICAL: CK0802 (Allogeneic, Cryopreserved, Cord blood-derived T-regulatory cells, cells that are not HLA matched)
Subjects will receive seven planned doses of CK0802 on study day +1, +3 (+/-1 day), +5 (+/-1 day), +7 (+/- 2 day), +14 (+/- 3 days), +21 (+/-3 days) an...